Brensocatib

A drug used in the treatment of bronchiectasis

Brensocatib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Brensocatib is an investigational drug that is being studied for the treatment of bronchiectasis, a chronic condition characterized by the abnormal widening of the bronchi or their branches, causing a risk of infection. It is a small molecule inhibitor of the enzyme dipeptidyl peptidase I (DPP1), which plays a role in the activation of neutrophil serine proteases.

Mechanism of Action

Brensocatib works by inhibiting the activity of DPP1, an enzyme responsible for the activation of neutrophil serine proteases such as neutrophil elastase, proteinase 3, and cathepsin G. These proteases are involved in the inflammatory response and tissue damage seen in bronchiectasis. By inhibiting DPP1, brensocatib reduces the activity of these proteases, thereby decreasing inflammation and tissue damage in the lungs.

Clinical Development

Brensocatib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with bronchiectasis. Early studies have shown that it can reduce the levels of neutrophil elastase in the sputum of patients, which is a marker of inflammation and disease activity in bronchiectasis.

Potential Benefits

The use of brensocatib in bronchiectasis aims to reduce the frequency and severity of exacerbations, improve lung function, and enhance the quality of life for patients. By targeting the underlying inflammatory processes, brensocatib has the potential to modify the course of the disease rather than just treating the symptoms.

Side Effects

As with any investigational drug, the safety profile of brensocatib is still being established. Common side effects observed in clinical trials include headache, nausea, and diarrhea. More serious side effects are being monitored as the drug progresses through clinical trials.

Research and Development

Brensocatib is being developed by Insmed Incorporated, a biopharmaceutical company focused on developing therapies for serious and rare diseases. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of bronchiectasis.

Related Pages

• Bronchiectasis
• Neutrophil elastase
• Dipeptidyl peptidase I
• Orphan drug